Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.
| Revenue (TTM) | $830.81M |
| Gross Profit (TTM) | $816.73M |
| EBITDA | $8.08M |
| Operating Margin | 16.10% |
| Return on Equity | 8.23% |
| Return on Assets | 0.47% |
| Revenue/Share (TTM) | $7.97 |
| Book Value | $6.54 |
| Price-to-Book | 18.00 |
| Price-to-Sales (TTM) | 15.11 |
| EV/Revenue | 14.93 |
| EV/EBITDA | 1405.48 |
| Quarterly Earnings Growth (YoY) | 24.10% |
| Quarterly Revenue Growth (YoY) | 31.70% |
| Shares Outstanding | $108.10M |
| Float | $96.47M |
| % Insiders | 11.47% |
| % Institutions | 76.86% |
Volatility is currently expanding
Corcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.
Corcept's Korlym sales rise 6.2% in H1 2026 as demand grows, while Lifyorli's launch offers a path to diversify revenues.
Institutions keep buying Corcept Therapeutics Incorporated (CORT) shares in big volumes, sending them up 1,016% since 2017 and on the cusp of joining the S&P MidCap 400 index.
Corcept Therapeutics is evolving into a multi-engine growth platform, driven by expanding Cushing's and a rapid oncology ramp with Lifyorli. CORT delivered strong 2Q26 results: $256.1M revenue (+32% YoY), $47.6M Lifyorli launch, and maintained profitability despite elevated launch expenses. CATALYST and MOMENTUM studies reveal Cushing's is more prevalent than previously thought, structurally expanding the addressable market and supporting multi-billion-dollar revenue potential.
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Corcept Therapeutics is rated Strong Buy with $163 one-year and $222 two-year price targets, driven by explosive revenue and margin expansion. Lifyorli's rapid launch for platinum-resistant ovarian cancer and Korlym's resilient growth underpin 44%+ revenue growth and 98% gross margins, fueling EPS leverage. Based on my Lifyorli model, Street revenue and EPS estimates could be significantly low.
President Donald Trump disclosed a position in Corcept Therapeutics (NASDAQ: CORT) on March 4, when the pharmaceutical company was trading at $35.69.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
CORT discovers, develops, and sells medications to treat severe metabolic, oncologic, and psychiatric disorders, focusing on the hormone cortisol (over 1,000 proprietary modulators) as well as Cushing's syndrome.
Corcept Therapeutics remains a 'Hold' as LIFYORLI's strong launch and clinical demand are already reflected in a premium valuation. LIFYORLI generated $47.6M in its first full quarter, with management targeting $1B+ US peak revenue and global NPV estimated at $4.24B. CORT's pipeline offers upside, notably with relacorilant in earlier PROC lines and EU approval pending, but non-LIFYORLI assets remain speculative.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CORT and any ticker you trade — then tracks every position and per-strategy win rate.
